A carregar...
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
Carfilzomib, a selective proteasome inhibitor (PI), is approved for the treatment of patients with relapsed or refractory multiple myeloma (MM). Combination regimens incorporating a PI and immunomodulatory drug (IMiD) have been associated with deep responses and extended survival in patients with ne...
Na minha lista:
| Publicado no: | Leukemia |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group UK
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6756042/ https://ncbi.nlm.nih.gov/pubmed/31341235 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-019-0517-6 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|